$ cat ./records/gates-foundation-co-funds-pediatric-dengue-vaccine-initiative-wit-2004.txt
Gates Foundation Co-Funds Pediatric Dengue Vaccine Initiative with PATH to Advance Dengvaxia
[RECORD.TXT] · cat --full
In 2004, the Gates Foundation co-funded the Pediatric Dengue Vaccine Initiative (PDVI), hosted at the International Vaccine Institute and implemented with PATH and WHO, to accelerate dengue vaccine development. PDVI provided Sanofi Pasteur with epidemiological and immunological data supporting clinical development of CYD-TDV, which became Dengvaxia — the first licensed dengue vaccine in 2015. Dengue infects 390 million people annually, with the burden falling disproportionately on children in tropical regions.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Microsoft issues a record $32 billion special dividend
Next →
Gates Foundation Commits $82.9 Million to Aeras for Tuberculosis Vaccines
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.